why choose us

Course: Anti–SARS-CoV-2 Monoclonal Antibody Distribution to High-risk Medicare Beneficiaries, 2020-2021

CME Credits: 1.00

Released: 2022-02-04

Monoclonal antibodies (mAbs) are highly effective in treating mild to moderate COVID-19 among nonhospitalized patients. Given limited supply, federal guidelines prioritize patients at higher risk of progression to hospitalization or mortality from COVID-19, with risk factors including age and comorbid conditions., Antibodies were initially allocated to states by the federal government, then distributed through suppliers in 2021. We assessed how the limited supply of mAb therapy was allocated to patients at highest risk of severe disease.


Educational Objective
To identify the key insights or developments described in this article


View Full Course